Diminished Drug R&D Could Be Price Of Closing Medicare "Donut Hole"
This article was originally published in The Pink Sheet Daily
Executive Summary
Price setting or negotiations could allow for seamless Medicare Rx coverage without overall cost increase, according to an analysis by Johns Hopkins' Anderson; trade-off of 45% price reduction would be limited research and development.
You may also be interested in...
Employer Options For Retiree Health Plans Outlined In Proposed Medicare Drug Rule
CMS is declining to predict whether the four retiree health coverage options available to employers and outlined in a Medicare proposed rule issued July 26 will be sufficient to stem the tide of employer dropouts
Medicare Rx Card Firms May Be Violating Pharmacy Access Mandate – Rep. Waxman
Sponsors' use of pharmacy passive acceptance agreements could be contributing to inaccurate participation data on Medicare Web site, House Democrats say. AdvancePCS, Anthem and Medco among firms in question.
HHS Secretary Urges Seniors To Delay Purchase Of Medicare Drug Card
Drug card sponsor list should be finalized within seven to 10 days of May 3 enrollment launch, Thompson tells Republican lawmakers. Senate Democrats renew call for HHS price negotiating authority.